Full-Time

Site Reliability Engineer

Posted on 8/7/2024

Virta Health

Virta Health

501-1,000 employees

Reverses type 2 diabetes through personalized care

Compensation Overview

$145.9k - $188.4k/yr

Senior

Remote in USA

Category
DevOps & Infrastructure
Site Reliability Engineering
Required Skills
Kubernetes
Python
Go
Terraform
Requirements
  • 5+ years of experience in cloud infrastructure automation using Kubernetes, with demonstrated ability to lead technical projects and mentor junior engineers. Bonus if that experience includes Anthos on GKE.
  • Strong experience in developing and managing services using GoLang or Python, with a proven ability to handle complex technical challenges.
  • Proficiency in Infrastructure as Code (IaC) tools, specifically Terraform, with experience leading technical implementations.
  • Strong knowledge of cloud security and compliance practices, preference towards HIPAA and HITRUST. Ideally, you have previously worked in a regulated environment.
  • Strong experience implementing observability for containerized applications.
  • Strong experience CI/CD principles and best practices, with experience implementing and optimizing pipelines with operational standards checks.
  • Excellent problem-solving and communication skills.
  • Demonstrated initiative leading by example, fostering collaboration, and driving projects to completion.
Responsibilities
  • Evangelizing SRE best practices across engineering with the goal of ensuring the high availability and performance of our cloud infrastructure.
  • Support infrastructure and product teams in analyzing and enhancing the scalability, reliability, and observability of our containerized systems.
  • Develop and maintain infrastructure automation to manage and scale standardized, repeatable infrastructure.
  • Develop testing infrastructure to improve application quality.
  • Lead continuous improvement initiatives within the team and collaborate with other teams to enhance engineering processes.
  • Lead the development and maintenance of CI/CD pipelines, ensuring efficient and reliable deployment of applications.
  • Provide mentorship and technical guidance to engineers, fostering a culture of collaboration and continuous learning.
  • Collaborate with our InfoSec team to ensure compliance requirements are implemented in the software development lifecycle.
  • Provide technical support and troubleshoot infrastructure-related issues, both during development and in production environments.

Virta Health focuses on reversing type 2 diabetes through a combination of personalized nutrition, continuous remote care, and behavioral science. Their treatment is designed for individuals diagnosed with type 2 diabetes, healthcare providers, and enterprise partners like employers and health plans. The company operates on a performance-based model, meaning they only receive payment if they achieve successful outcomes, such as reversing diabetes in their patients. This aligns their financial incentives with patient health improvements and encourages the adoption of their services. Virta Health's goal is to reverse type 2 diabetes in 100 million people, setting them apart from competitors who typically focus on managing the condition rather than reversing it.

Company Size

501-1,000

Company Stage

Series E

Total Funding

$373M

Headquarters

Denver, Colorado

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Virta's approach reduces GLP-1 medication use, leading to significant cost savings for payers.
  • The company's rapid growth is evidenced by over $100M in annualized revenue.
  • Virta's treatment shows sustained weight loss post-GLP-1 deprescription, unlike other treatments.

What critics are saying

  • Increased competition in diabetes reversal could threaten Virta's market share.
  • Rising demand for GLP-1 medications may challenge Virta's nutrition-first approach.
  • Economic downturns could reduce healthcare spending, impacting Virta's revenue.

What makes Virta Health unique

  • Virta Health offers a drug-free diabetes reversal program, unlike traditional management methods.
  • Their performance-based model aligns financial incentives with successful patient outcomes.
  • Virta's continuous remote care platform provides personalized nutrition and behavioral support.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote-first work environment

Flexible work hours & time off policy

Health insurance

Paid parental leave

Free Virta treatment & family discount

Internet, home office, learning & development stipends

Employee resource groups

401K & ROTH contribution

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

0%

2 year growth

-2%
Hit Consultant
Apr 4th, 2025
Virta Health Cuts Glp-1 Use For Weight Loss Over 50%, Driving Cost Savings For Payers

Source: Virta HealthWhat You Should Know:– Virta Health, a leader in diabetes reversal and sustainable weight loss through its nutrition-first methodology, has announced early results from its recently launched Sustainable Weight Loss GLP-1 prescribing capabilities.– These outcomes signal a potentially transformative shift in obesity and weight loss management, offering organizations a responsible framework for covering GLP-1 medications while actively reducing reliance and controlling overall costs.Addressing the Growing GLP-1 Cost CrisisAs organizations grapple with the escalating costs of GLP-1 medications, projected to exceed $100B annually, the need for a responsible and cost-effective approach to their coverage has become critical. This urgency is amplified by the fact that 69% of consumers express a preference for losing weight without medication, highlighting the demand for solutions that prioritize sustainable lifestyle changes over long-term drug dependency and its associated financial burden.Delivering Major Cost Savings for PayersExpanding upon Virta’s established Sustainable Weight Loss solution, its Responsible Prescribing approach is designed to empower employers, health plans, and pharmacy benefit managers with a comprehensive strategy. This strategy delivers best-in-class patient outcomes both with and without GLP-1 medications, providing a drug-free alternative, facilitating combination therapy when appropriate, and offering a structured pathway to discontinue medication when clinically suitable. Virta’s approach uniquely positions payers to access the most cost-effective solutions for long-term health improvements, strategically integrating weight loss medications as a component of care rather than the sole focus.Preliminary data from Virta’s current client base demonstrates the significant impact of its prescribing solution:Substantial Reduction in GLP-1 Utilization and Costs: Virta’s Responsible Prescribing has successfully prevented the ongoing use of GLP-1 medications in over 50% of current GLP-1 users¹, leading to significant cost savings for payers. Furthermore, across Virta’s entire Sustainable Weight Loss program, less than 25% of members are currently on GLP-1s, underscoring the effectiveness of Virta’s nutrition-first approach in guiding members toward alternative weight loss strategies.Virta’s Responsible Prescribing has successfully prevented the ongoing use of GLP-1 medications in over 50% of current GLP-1 users¹, leading to significant cost savings for payers. Furthermore, across Virta’s entire Sustainable Weight Loss program, less than 25% of members are currently on GLP-1s, underscoring the effectiveness of Virta’s nutrition-first approach in guiding members toward alternative weight loss strategies

Business Wire
Jan 10th, 2025
Virta Health Announces Record and Accelerating Growth at a Scale of More Than $100M in Annualized Revenue, Driven by Sustainable Weight Loss and GLP-1 Solutions

To help employers, health plans, and pharmacy benefit managers deliver best-in-class outcomes with or without GLP-1 medications, Virta recently launched Responsible Prescribing, an expansion of its SWL suite.

Hit Consultant
Aug 6th, 2024
Physicians Reveals Glp-1S For Weight Loss Are Overprescribed And Unsustainable

Physicians Reveals GLP-1s for Weight Loss are Overprescribed and Unsustainable by Jasmine Pennic 08/06/2024 Leave a Comment What You Should Know:  – A large majority of physicians feel GLP-1s are being overprescribed, according to a new survey from Virta Health, a leader in type 2 diabetes reversal.  – The Virta Health survey was conducted in partnership with Beresford Research and included 300 primary care providers, endocrinologists, and obesity specialists across the United States sheds light on the medical community’s views on the rapidly growing class of GLP-1 medications, often hailed as “miracle drugs” for weight loss.  Key Findings Reveals Skepticism About Weight Loss Drugs The key findings reveal significant concerns about the long-term efficacy, potential side effects, and overall impact of these medications on public health:  – Doubtful about long-term efficacy: Most physicians believe GLP-1 medications are not sustainable beyond two to three years and should not be used as a long-term solution. – Overprescription concerns: A large majority of physicians feel GLP-1s are being overprescribed and that lifestyle interventions should be prioritized. – Need for stricter guidelines: Physicians advocate for increased oversight through prior authorization and greater provider involvement in prescribing decisions. – Patient misconceptions: Many doctors report that patients have unrealistic expectations about the effectiveness and safety of GLP-1 medications. – Potential for increased healthcare costs: The widespread adoption of GLP-1s is expected to drive up healthcare costs due to increased demand and limited supply. – Concerns about health equity: Physicians are worried about the potential for increased health disparities as GLP-1 medications may not be equally accessible to all patients

Business Wire
Feb 29th, 2024
Virta Health Announces First-Of-Its-Kind Peer-Reviewed Study Proving Its Approach Is An Effective Off-Ramp From Glp-1S For Sustained Weight Loss

Following GLP-1 deprescription, weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to 2/3rds of weight loss after discontinuing the drug. (Graphic: Business Wire)Following GLP-1 deprescription, weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to 2/3rds of weight loss after discontinuing the drug. (Graphic: Business Wire)DENVER--(BUSINESS WIRE)--Virta Health has released first-of-its-kind, peer-reviewed data demonstrating the company’s approach to personalized nutrition therapy results in sustained weight loss after the discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1s), including Ozempic. Published today in Diabetes Therapy, the data demonstrates Virta is a powerful and sustainable off-ramp from GLP-1s.These outcomes stand in stark contrast to other real-world results of GLP-1 weight loss treatments. Discontinuing the medications has been shown to lead to rapid worsening of blood sugar and weight regain, even when accompanied by physical activity and calorie restriction. Additionally, as many as two out of three people on GLP-1s stop within a year and quickly regain the weight they lost, underscoring the need for an effective medication-free alternative and off-ramp from the medications to achieve sustainable results.The study assessed weight loss in two groups of Virta members with type 2 diabetes: those for whom (a) GLP-1s were fully deprescribed and (b) GLP-1s were continued

BioSpace
Feb 29th, 2024
Virta Health Announces First-of-its-Kind Peer-Reviewed Study Proving Its Approach Is an Effective Off-Ramp From GLP-1s for Sustained Weight Loss

DENVER-(BUSINESS WIRE)- Virta Health has released first-of-its-kind, peer-reviewed data demonstrating the company's approach to personalized nutrition therapy results in sustained weight loss after the discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1s), including Ozempic.

INACTIVE